

FIG. 1




FIG. 2




FIG. 3A




FIG. 3B




FIG. 3C




FIG. 3D




FIG. 3E




FIG. 4




FIG. 5A




FIG. 5B




FIG. 5C




FIG. 5D




FIG. 6

Assay Name	(-)JRET	(*)JRET
5-HT1A (h) (agonist radioligand)	55	55
5-HT1B (h) (antagonist radioligand)	0	28
5-HT2A (h) (antagonist radioligand)	23	55
5-HT2B (h) (agonist radioligand)	37	105
5-HT3 (h) (antagonist radioligand)	-4	-7
5-HT5a (h) (agonist radioligand)	75	55
5-HT5 (h) (agonist radioligand)	38	53
5-HT7 (h) (agonist radioligand)	25	54
A1 (h) (antagonist radioligand)	15	15
A2A (h) (agonist radioligand)	-6	-15
A3 (h) (agonist radioligand)	14	13
alpha 1 (non-selective) (antagonist radioligand)	5	11
alpha 2 (non-selective) (antagonist radioligand)	0	-6
AT1 (h) (antagonist radioligand)	0	-4
B2 (h) (agonist radioligand)	-11	-6
beta 1 (h) (agonist radioligand)	-3	0
beta 2 (h) (antagonist radioligand)	1	-6
B2D (control) (agonist radioligand)	-6	-13
Ca2+ channel (L, verapamil site) (phenylalkylamine) (antagonist radioligand)	2	13
CB1 (h) (agonist radioligand)	3	-1
CCR1 (CCKA) (h) (agonist radioligand)	21	6
CCR1 (h) (agonist radioligand)	-5	-3
Cl- channel (GABA-gated) (antagonist radioligand)	6	6
CXCR2 (IL-8R) (h) (agonist radioligand)	-1	-7
D1 (h) (antagonist radioligand)	-1	27
D25 (h) (antagonist radioligand)	-3	4
delta (DOP) (h) (agonist radioligand)	4	-3
EP4 (h) (agonist radioligand)	1	-1
ETA (h) (agonist radioligand)	12	12
GABA (non-selective) (agonist radioligand)	3	-4
GAL2 (h) (agonist radioligand)	1	5
H1 (h) (antagonist radioligand)	-4	-13
H2 (h) (antagonist radioligand)	-4	-4
kappa (h) (KOP) (agonist radioligand)	15	7
KV channel (antagonist radioligand)	6	3
M1 (h) (antagonist radioligand)	0	-4
M2 (h) (antagonist radioligand)	-3	-1
M3 (h) (antagonist radioligand)	-7	4
MC4 (h) (agonist radioligand)	5	5
MT1 (ML1A) (h) (agonist radioligand)	25	21
mu (MOP) (h) (agonist radioligand)	-2	-6
Na+ channel (site 2) (antagonist radioligand)	4	-17
NK2 (h) (agonist radioligand)	57	35
NK3 (h) (antagonist radioligand)	-27	-20
NOP (ORL1) (h) (agonist radioligand)	-18	-24
NTS1 (NTS) (h) (agonist radioligand)	9	-7
SKCa channel (antagonist radioligand)	-1	-5
sst (non-selective) (agonist radioligand)	-9	-15
Transporter: 5-HT (h) (antagonist radioligand)	-14	-9
Transporter: DA (h) (antagonist radioligand)	15	4
Transporter: NET (h) (antagonist radioligand)	-6	-4
V1a (h) (agonist radioligand)	7	15
VPKC1 (VIP1) (h) (agonist radioligand)	-4	-2
Y1 (h) (agonist radioligand)	8	5
Y2 (h) (agonist radioligand)	1	-1

FIG. 7





FIG. 8


Injection Volume : 15 uL
Data File Name : 01042021B1.lcd
Method File Name : CHIRAL-MET-B50-1.0mL.lcm
Report File Name : Default.lcr
Data Acquired : 01-04-2021 15:50:44
Description : COLUMN: CHIRAL PAK IC(250mmX 4.6mm,5µm)
Mobile Phase A :0.1%DEA in n-Hexane
Mobile Phase B :IPA
A:B:50:50
Flow:1.0mL/min



PeakTable				
Peak#	Ret. Time	Area	Height	Area %
1	7.711	3788998	231995	42.180
2	9.890	5193924	249782	57.820
Total		8982922	481778	100.000

FIG. 9


Injection Volume : 15 uL
Data File Name : 01042021B2.lcd
Method File Name : CHIRAL-MET-B50-1.0mL.lcm
Report File Name : Default.lcr
Data Acquired : 01-04-2021 16:16:22
Description : COLUMN: CHIRAL PAK IC(250mmX 4.6mm, 5µm)
Mobile Phase A : 0.1%DEA in n-Hexane
Mobile Phase B : IPA
A:B:50:50
Flow: 1.0mL/min



PeakTable				
Peak#	Ret. Time	Area	Height	Area %
1	7.805	9642643	562879	100.000
Total		9642643	562879	100.000

FIG. 10

Injection Volume : 10 μ L
Data File Name : 01042021B3.lcd
Method File Name : CHIRAL-MET-B50-1.0mL.lcm
Report File Name : Default.lcr
Data Acquired : 01-04-2021 16:34:43
Description : COLUMN: CHIRAL PAK IC(250mmX 4.6mm,5 μ m)
Mobile Phase A : 0.1%DEA in n-Hexane
Mobile Phase B : IPA
A:B:50:50
Flow:1.0mL/min



PeakTable				
Peak#	Ret. Time	Area	Height	Area %
1	7.968	31705	1915	0.561
2	10.140	5619691	267077	99.439
Total		5651396	268992	100.000

